Skip to Main Content

Paper Details

Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy.
Cancers (Basel)
7
2022
E2F, Early-Stage Lung Adenocarcinoma, LUAD, LUAD cells, Lung adenocarcinoma, Lung cancer, MDM2, MDM2 locus, MMPs, NSCLC, PEG10, RNA, cancer, chromosome 12q15, lung adenocarcinoma, lung cancer, men, non-small cell lung cancer, p53, p53 mutant, patient, patients, tumor, wild, wild-type LUAD cells, women
Author NameAffiliation
Seungyeul Yoo
Jun ZhuTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Jun ZhuIcahn Institute for Data Science and Genomic Technology
Jun ZhuIcahn School of Medicine at Mount Sinai
Jun Zhu
Pierre P MassionVanderbilt University Medical Center
Pierre P MassionVanderbilt University Medical Center
Alain C Borczuk
  • 1 - 8

Datasets

Release 1.2